All rights reserved. Comparatively, 80.7% of Edwards Lifesciences shares are held by institutional investors. Teladoc Health is trading at a lower price-to-earnings ratio than Baxter International, indicating that it is currently the more affordable of the two stocks.Teladoc Health has a beta of 0.44, meaning that its stock price is 56% less volatile than the S&P 500. Takeda Pharmaceutical has a consensus price target of $24.75, suggesting a potential upside of 35.62%. Teladoc Health is trading at a lower price-to-earnings ratio than Edwards Lifesciences, indicating that it is currently the more affordable of the two stocks.97.1% of Teladoc Health shares are held by institutional investors.
Comparatively, 89.9% of Illumina shares are held by institutional investors. Illumina has a consensus price target of $340.4667, suggesting a potential downside of 12.29%. Comparatively, 3.7% of Takeda Pharmaceutical shares are held by institutional investors. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.Teladoc Health has a beta of 0.44, meaning that its stock price is 56% less volatile than the S&P 500. All content of the Dow Jones branded indices © S&P Dow Jones Indices LLC 2019 and/or its affiliates. View which stocks are hot on social media with MarketBeat's trending stocks report.Baxter International has higher revenue and earnings than Teladoc Health. Our services span the spectrum of healthcare needs, from simple to complex. Given Edwards Lifesciences' stronger consensus rating and higher probable upside, analysts clearly believe Edwards Lifesciences is more favorable than Teladoc Health.Receive a free world-class investing education from MarketBeat. Our services span the spectrum of healthcare needs, from simple to complex. Factset: FactSet Research Systems Inc.2019. 3.4% of Teladoc Health shares are held by insiders. 3.4% of Teladoc Health shares are held by insiders. We seamlessly connect general medical, mental health, and complex care to … Teladoc Health is trading at a lower price-to-earnings ratio than Illumina, indicating that it is currently the more affordable of the two stocks.97.1% of Teladoc Health shares are held by institutional investors. In the table, you'll find all the components (individual stock symbols) found in that sector, ranking them by their Weighted Alpha (a rating of growth patterns in a one-year period).© 2020 Barchart.com, Inc. All Rights Reserved.Barchart.com takes this Alpha (measure of how much a stock has changed in the one-year period) and weights this, assigning more weight to recent activity, and less (0.5 factor) to activity at the beginning of the period. View which stocks are hot on social media with MarketBeat's trending stocks report.Illumina presently has a consensus target price of $340.4667, indicating a potential downside of 12.09%.
Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.Takeda Pharmaceutical has a beta of 1, suggesting that its stock price has a similar volatility profile to the S&P 500.Comparatively, Teladoc Health has a beta of 0.44, suggesting that its stock price is 56% less volatile than the S&P 500.Boston Scientific beats Teladoc Health on 12 of the 15 factors compared between the two stocks.80.7% of Edwards Lifesciences shares are owned by institutional investors.